Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
23 févr. 2023 16h05 HE
|
Relay Therapeutics, Inc.
Advanced RLY-4008: Reported interim data with 88% overall response rate at pivotal dose and 63% across all doses in pan-FGFR treatment-naïve, FGFR2-fusion cholangiocarcinoma patients & announced...
Relay Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
16 févr. 2023 16h05 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics to Participate in Guggenheim Healthcare Talks | Oncology Day
02 févr. 2023 07h30 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks | Oncology Day on...
Relay Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 07h30 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
07 nov. 2022 07h30 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two fireside chats this month at the H.C. Wainwright 3rd Annual Precision...
Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
03 nov. 2022 16h05 HE
|
Relay Therapeutics, Inc.
Shared 88% overall response rate (ORR) from interim data of RLY-4008 in pan-FGFR treatment (FGFRi)-naïve FGFR2-fusion cholangiocarcinoma (CCA) patients treated at the pivotal dose at European Society...
Relay Therapeutics to Announce Third Quarter 2022 Financial Results and Corporate Highlights
27 oct. 2022 16h05 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Precision Oncology Conference
26 sept. 2022 07h30 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
12 sept. 2022 21h30 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics Announces Proposed Public Offering of Common Stock
12 sept. 2022 07h00 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...